Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multi-cohort trial of SAR408701 in CEACAM5-positive advanced solid tumors
2020-003096-18Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tusamitamab ravtansine in breast cancer and pancreatic adenocarcinoma (PDAC), sponsored by Sanofi. Primary endpoint: Objective Response Rate (ORR). Started Nov 2020; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
breast cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2020-003096-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003096-18.